The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Montreal-based Valeant said on July 17 that it will launch its hostile offer for Allergan this week.
Montreal-based Valeant said on July 17 that it will launch its hostile offer for Allergan this week.
(RYAN REMIORZ/THE CANADIAN PRESS)

Valeant’s best shot at Allergan may lie in taking a breather

An abstinent Valeant Pharmaceuticals International might enable the Allergan deal. The slug fest between the acquisitive drugs company and its reluctant $50-billion-plus (U.S.) quarry could drag out for months. In the meantime, Valeant will produce results less muddled by M&A. They could be the deciding factor.